[go: up one dir, main page]

CL2018000489A1 - Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona - Google Patents

Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Info

Publication number
CL2018000489A1
CL2018000489A1 CL2018000489A CL2018000489A CL2018000489A1 CL 2018000489 A1 CL2018000489 A1 CL 2018000489A1 CL 2018000489 A CL2018000489 A CL 2018000489A CL 2018000489 A CL2018000489 A CL 2018000489A CL 2018000489 A1 CL2018000489 A1 CL 2018000489A1
Authority
CL
Chile
Prior art keywords
diona
metil
quinazolin
piperidin
oxo
Prior art date
Application number
CL2018000489A
Other languages
English (en)
Inventor
Indrajit Ghosh
Daozhong Zou
Colin Walters
William Bowen
Yali Sun
Jay Brumfield
Xiaoxuan Shen
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2018000489A1 publication Critical patent/CL2018000489A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

FORMULACIONES DE 3-(5-AMINO-2-METIL-4-OXO-4H-QUINAZOLIN-3-IL)-PIPERIDIN-2,6-DIONA
CL2018000489A 2015-08-27 2018-02-22 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona CL2018000489A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210923P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
CL2018000489A1 true CL2018000489A1 (es) 2018-08-03

Family

ID=56883865

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000489A CL2018000489A1 (es) 2015-08-27 2018-02-22 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Country Status (17)

Country Link
US (1) US10064863B2 (es)
EP (1) EP3340969B1 (es)
JP (1) JP2018525422A (es)
KR (1) KR20180039084A (es)
CN (1) CN107921004A (es)
AU (1) AU2016310340A1 (es)
BR (1) BR112018003335A2 (es)
CA (1) CA2996641A1 (es)
CL (1) CL2018000489A1 (es)
CO (1) CO2018002545A2 (es)
EA (1) EA201890585A1 (es)
EC (1) ECSP18023544A (es)
ES (1) ES2865289T3 (es)
HK (1) HK1252415A1 (es)
IL (1) IL257666A (es)
MX (1) MX2018002487A (es)
WO (1) WO2017035443A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6727237B2 (ja) 2015-07-02 2020-07-22 セルジーン コーポレイション 血液がん及び固形腫瘍の治療のための併用療法
MX2018006779A (es) 2015-12-02 2018-08-01 Celgene Corp Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.
MX2022004686A (es) * 2019-10-21 2022-05-10 Celgene Corp Composiciones farmaceuticas que comprenden (s)-2-(2,6-dioxopiperid in-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1- il)metil)bencil)indolin-1,3-diona y metodos de uso de las mismas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
PT2420498T (pt) 2006-09-26 2017-08-01 Celgene Corp Derivados de quinazolina substituídos em 5 como agentes anticancro
JP5959543B2 (ja) * 2011-03-11 2016-08-02 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用
US20140148473A1 (en) * 2011-03-11 2014-05-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
AR099385A1 (es) * 2014-01-15 2016-07-20 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona

Also Published As

Publication number Publication date
EP3340969A1 (en) 2018-07-04
US10064863B2 (en) 2018-09-04
EP3340969B1 (en) 2021-02-17
CN107921004A (zh) 2018-04-17
AU2016310340A1 (en) 2018-03-15
ES2865289T3 (es) 2021-10-15
KR20180039084A (ko) 2018-04-17
EA201890585A1 (ru) 2018-11-30
JP2018525422A (ja) 2018-09-06
WO2017035443A1 (en) 2017-03-02
HK1252415A1 (zh) 2019-05-24
IL257666A (en) 2018-04-30
CA2996641A1 (en) 2017-03-02
ECSP18023544A (es) 2018-04-30
MX2018002487A (es) 2018-06-15
CO2018002545A2 (es) 2018-07-10
BR112018003335A2 (pt) 2018-09-25
US20170056323A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
EP3490539A4 (en) NEW ORAL FORMULATION.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2018003443A1 (es) Tratamientos para el cancer.
MX384883B (es) Métodos para usar activadores de piruvato cinasa.
EP3408306A4 (en) Radiation curing composition
LT3768284T (lt) Enterecoccus flagelino kompozicijos, skirtos panaudoti terapijai
TWD177105S (zh) 奶嘴
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
CL2015002084S1 (es) Accesorio para calzado.
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
CL2019001038A1 (es) Composición para el cuidado bucal.
EA201691924A1 (ru) Фармацевтические композиции
BR112018012116A2 (pt) terapia intravesical para câncer de bexiga
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
BR112017002139A2 (pt) ?método para preparar um composto?
TR201908795T4 (tr) Bi̇r şeki̇llendi̇ri̇lebi̇li̇r kütleni̇n şeki̇llendi̇ri̇lmesi̇ i̇çi̇n ci̇haz
CL2019001624A1 (es) Composición para el cuidado bucal.
CL2019000323A1 (es) Composición para el cuidado bucal.
CL2019003071A1 (es) Composiciones para el cuidado bucal.
EA201700060A1 (ru) Терапевтическое средство для кератоконъюнктивальных расстройств
LT3493849T (lt) N,n-bis-2-merkaptoetilizoftalamido naujas panaudojimas
CL2016003220A1 (es) Formulaciones intravaginales que comprenden gnrh.
BR112017018293A2 (pt) brocas dentárias.